Table 3a.
Association between the presence of anti-gliadin antibodies and diabetes-related autoantibodies (the risk to develop anti-gliadin antibody dependent on the presence or absence of GADAb and/or IA2Ab)
| Absolute/% | AGA IgG | Rel. risk (CI) | AGA IgA | Rel. risk (CI) |
|---|---|---|---|---|
| GADAb – IA2Ab− | 3/85 3·5% | 1 | 3/85 3·5% | 1 |
| GADAb – IA2Ab+ | 3/19 15·8% | 4·47 (0·98–20·48) | 2/19 10·5% | 2·98 (0·53–16·63) |
| GADAb + IA2Ab− | 6/36 16·7% | 4·72 (1·25–17·85) | 4/36 11·1% | 3·15 (0·74–13·36) |
| GADAb + IA2Ab+ | 4/12 33·3% | 9·44 (2·4–37·15) | 3/12 25% | 7·08 (1·61–31·17) |
| Trend (statistical significance) | P = 0·00054 | P = 0·0096 |